BNR Stock Overview
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Burning Rock Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.72 |
| 52 Week High | US$3.25 |
| 52 Week Low | US$0.57 |
| Beta | 0.23 |
| 1 Month Change | -7.34% |
| 3 Month Change | -25.77% |
| 1 Year Change | -74.10% |
| 3 Year Change | -97.58% |
| 5 Year Change | n/a |
| Change since IPO | -97.08% |
Recent News & Updates
Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?
Mar 25
There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues
Feb 01Recent updates
Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?
Mar 25There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues
Feb 01Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jul 12Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?
Apr 28We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully
Dec 23Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?
Sep 20Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M
Aug 31Burning Rock Localizes As Investors Grow Impatient
Jun 06We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely
Mar 24Following Rough Year, Is Burning Rock Set To Turn The Corner?
Nov 17Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?
Aug 27A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)
Jul 23Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?
May 13Burning Rock Biotech Expands Test Portfolio In Bid For Growth
Dec 30Burning Rock inks license pact with Oncocyte Corporation
Dec 15Burning Rock Biotech prices upsized offering of 2.243M ADSs at $25.75/ADS
Dec 04Burning Rock Biotech EPS misses by $0.08, beats on revenue
Nov 20Shareholder Returns
| BNR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.0% | -2.5% | -3.2% |
| 1Y | -74.1% | -3.7% | 19.3% |
Return vs Industry: BNR underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: BNR underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| BNR volatility | |
|---|---|
| BNR Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BNR's share price has been volatile over the past 3 months.
Volatility Over Time: BNR's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1,138 | Yusheng Han | www.brbiotech.com |
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Burning Rock Biotech Limited Fundamentals Summary
| BNR fundamental statistics | |
|---|---|
| Market cap | US$75.92m |
| Earnings (TTM) | -US$90.29m |
| Revenue (TTM) | US$74.23m |
1.0x
P/S Ratio-0.8x
P/E RatioIs BNR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNR income statement (TTM) | |
|---|---|
| Revenue | CN¥537.44m |
| Cost of Revenue | CN¥174.21m |
| Gross Profit | CN¥363.23m |
| Other Expenses | CN¥1.02b |
| Earnings | -CN¥653.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.20 |
| Gross Margin | 67.59% |
| Net Profit Margin | -121.63% |
| Debt/Equity Ratio | 0% |
How did BNR perform over the long term?
See historical performance and comparison